Efficacy of l-Arginine treatment in patients with HTLV-1-associated neurological disease.
- 2022-12-22
- Clinical Trial · n = 20
- Annals of clinical and translational neurology 10(2)
- Satoshi Nozuma
- Eiji Matsuura
- Yuichi Tashiro
- Ryusei Nagata
- Masahiro Ando
- Yu Hiramatsu
- Yujiro Higuchi
- Yusuke Sakiyama
- Akihiro Hashiguchi
- Kumiko Michizono
- Keiko Higashi
- Toshio Matsuzaki
- Daisuke Kodama
- Masakazu Tanaka
- Yoshihisa Yamano
- Takashi Moritoyo
- Ryuji Kubota
- Hiroshi Takashima
- PubMed: 36547017
- DOI: 10.1002/acn3.51715
- Moderate evidence
- Clinical
a significant improvement was detected between baseline and Day 14 (-9.4%, 95% CI -16.6% to -2.2%; P = 0.01)
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes
- Dose
- 20 g/day